Sanofi
Ana holds a Veterinary License, Master’s, and PhD in Veterinary Medicine from the Faculty of Veterinary Medicine in Iași, Romania. She began her career in France in the pharmaceutical industry, joining Theravectys, a biotech company affiliated with the Institut Pasteur. There, she served as Deputy Manager of the Immunomonitoring Platform and later advanced to Manager of Preclinical Evaluation and Immunomonitoring position. In this role, Ana oversaw both internal and external resources for the in vivo and in vitro preclinical evaluation of various vaccine candidates (veterinary and human purposes). Her work included characterizing immune responses, toxicity, biodistribution, efficacy, and carcinogenicity of lentiviral vectors across multiple animal models, including humanized and immunocompromised mice, immunocompetent mice, rats, non-human primates, pigs, dogs, horses, and cats.
Driven by a strong interest in Advanced Therapy Medicinal Products (ATMPs), Ana joined I-STEM, a research institute funded by AFM-Téléthon, as a Preclinical Project Manager. There, she contributed to the cross-functional management of cell-based therapy projects, gaining valuable experience in the development of novel cell type based therapies and medical devices. Her work spanned early development, CMC challenges, preclinical studies, and clinical trial implementation.
Ana currently works at Sanofi as a Senior Nonclinical Safety Project Expert. In this role, she collaborates closely with pharmacologists, pharmacokineticists, and other specialists to evaluate a wide range of therapeutic modalities. Passionate about toxicology, she is committed to identifying and characterizing potential toxicities in preclinical systems to better anticipate outcomes in clinical trials.
Dr. Rahul Purwar is a professor at Department of Biosciences and Bioengineering at IIT Bombay. He holds a Ph.D. in Molecular Medicine from Hannover Medical School, Germany. Dr. Rahul’s professional journey spans various prestigious institutions and roles. He started his...
En savoir +After a master's degree in genetics and a Ph.D. on the role of Gas6 protein and precursor cells in steatohepatitis and hepatic fibrosis, Agnès advised companies in many sectors, particularly in industry, as a consultant in innovation financing. She was...
En savoir +Sai Kiang Lim is a renowned molecular biologist and biochemist who has made significant contributions to the understanding of the underlying molecular and cellular mechanisms of diseases and the development of therapies. She received her Bachelor of Science in Biochemistry...
En savoir +Dr. van der Stegen is working to genetically engineer stem cell-derived T-cells, cells of the immune system, that will be specifically directed towards attacking cancer cells. If successful, this would lay the foundation for further therapeutic application of the unlimited,...
En savoir +Farida Djouad is a Research Director at Inserm and leads the "Mechanisms of Regeneration and Therapeutic Applications" group at the Institute of Regenerative Medicine and Biotherapy (IRMB) in Montpellier, France. She obtained her PhD in Biology and Health from the...
En savoir +Martin Pule is Clinical Senior Lecturer in the Dept. of Haematology at UCL Cancer Institute and Honorary Consultant in Haematology at University College London Hospital. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment,...
En savoir +Helene NEGRE, PharmD, PhD, developed her expertise in Cell & Gene Therapy bioproduction through more than 20 years of experience in Advanced Therapy Medicinal Product (ATMPs). Initially, she worked at Pitié-Salpêtrière Hospital (AP-HP) in the Biotherapy department. In 2014, she...
En savoir +Amanda Silva Brun (PharmD, PhD, Harvard Business School alumna) is a Research Director at CNRS and Université Paris Cité. Her work at the NABI laboratory (UMR8175) and the IVETh industrial integrator focuses on innovative approaches in biotherapy and the bioproduction...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +Claire is a Consultant Haematologist at UCLH and Associate Professor in Haematology at UCL with a particular interest in adoptive cell therapies. She completed an Immunotherapy PhD at UCL with Karl Peggs and subsequently undertook a clinician scientist role with...
En savoir +Professor Lietzan focuses her scholarship and teaching primarily in the areas of FDA law (and health law more generally), administrative law, and intellectual property. She brings to her scholarship and teaching eighteen years of private practice experience, eight of them...
En savoir +European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...
En savoir +Laure obtained a PhD in Genetics at Imagine Institute of Necker hospital in Paris. During her PhD years, she was also implicated on the organization and communication of scientific events by being member of Young researchers of Imagine Institute association....
En savoir +After studying biology at the University of Sciences in Besançon, Sylvie defended her thesis based on cytogenetic and molecular prenatal diagnostic tools in Pr. Bresson's cytogenetics laboratories in Besançon. Then she went to Montreal, Quebec, as a laboratory coordinator at...
En savoir +Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...
En savoir +Damia Benchabane joined Alira Health with 11 years of Regulatory Affairs experience in the pharmaceutical industry. Damia has worked in start-ups as well as mid-to-large pharmaceutical companies including LFB Biomédicaments, AB Science, Novartis, and GSK. Damia has extensive experience in...
En savoir +Jessica Gobbo is an accomplished clinician-researcher with a profound specialization in oncology and translational medicine. She works as a researcher in the early-phase clinical trials unit at the Centre Georges-François Leclerc (CLCC) in Dijon and is a key member of...
En savoir +Jean-Luc Schlick holds a PhD in Biochemistry and Molecular Biology from Sciences University of Franche-Comté (Besancon, Fr). He is a co-founder of RD-BIOTECH SAS founded in 2002 with Philippe Dulieu and Jean-François Musard. In 2002, he was head of the...
En savoir +With 15 years' experience as a manager in the hotel and seminar industry, I joined the PMT events department in 2020. I was lucky enough to take part in the Innovative Therapies Days adventure from its very first edition in...
En savoir +George Alzeeb is an accomplished cancer researcher specializing in immunotherapy, 3D tumor modeling, and translational oncology. Currently Innovation Manager at Brenus Pharma, he drives the development of cutting-edge therapeutic strategies, including allogeneic immunotherapy. Dr. Alzeeb earned his PhD in Oncology,...
En savoir +JCM is the Associate Director for Tissues, Cells and Advanced Therapies (TCAT) at the SNBTS and an Honorary Reader at University of Edinburgh. As an experienced experimental haematologist and stem cell biologist Jo’s focus is the assessment, development and translation...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...
En savoir +Dr. John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development...
En savoir +Professor of Internal Medicine, AP-HP Saint-Louis University Hospital (Paris Cité University, France); Adjunct Professor, McGill University (Canada) Prof. Dominique Farge is a leading expert in stem cell and immune cell therapies for autoimmune diseases. For over 30 years, she has...
En savoir +Danièle Noël is currently Research Director at Inserm at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier. She received her PhD in Health Biology from Bordeaux University in 1992. She completed a post-doctoral fellowship at the Institute of...
En savoir +Celine ELIE-CAILLE obtained her Ph.D degree in enzymatic engineering from the University of Technology of Compiègne (UTC, France) in 2003. After a post-doctoral position at the BIOTEC Institute in Dresden (Germany) in 2004-2006 where she acquired skills in atomic force...
En savoir +PhD in molecular and cell therpay, research director at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR), Dr Christophe Ferrand is also the founder of advesya biotech company, a French clinical-stage biotech company founded in 2020....
En savoir +